Studies on microparticles (MPs) in patients with antiphospholipid antibodies (aPL) are sparse and inconclusive. The relation between MPs and different aPL antibody profiles has never been tested. We evaluated the presence of platelet and endothelial microparticles in patients positive for IgG anti-β2-glycoprotein I (aβ2GPI) antibodies according to triple, double and single positive aPL profiles.
Methods
Megamix (Biocytex) was used to set up the MPs gating according to the datasheet. Markers of Platelet Microparticles (PMPs) were CD41a-PE and annexin-V-FITC that was used to determine phosphatidylserine (PS) exposure. CD144-FITC was used as a marker of Endothelial Microparticles (EMPs).
Results
The number of total MPs and EMPs was significantly higher in triple positive groups with respect to single positive group and showed a significant correlation with IgG aβ2GPI titers. The number PMPs was the lowest in triple positive group and inversely correlated with IgG aβ2GPI titers.
Conclusions
Elevated levels of total MPs and EMPs suggest a state of vascular activation in IgG aβ2GPI positive individuals according to the number of positive tests. PMPs may be fast cleared from circulation in high risk triple positive patients.
ArdoinSPShanahanJCPisetskyDS. The role of microparticles in inflammation and thrombosis. Scand J Immunol2007; 66: 159–165.
2.
ZahraSAndersonJAStirlingD, et al.Microparticles, malignancy and thrombosis. Br J Haematol2011; 152: 688–700.
3.
ThiagarajanPTaitJF. Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J Biol Chem1990; 265: 17420–17423.
4.
SinauridzeEIKireevDAPopenkoNY, et al.Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost2007; 97: 425–434.
5.
ConnorDEExnerTMaDD, et al.The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. Thromb Haemost2010; 103: 1044–1052.
6.
DasguptaSKLeAChavakisT, et al.Developmental endothelial locus-1 (Del-1) mediates clearance of platelet microparticles by the endothelium. Circulation2012; 125: 1664–1672.
7.
ChaturvediSAlluriRMcCraeKR. Extracellular vesicles in the antiphospholipid syndrome. Semin Thromb Hemost2018; 44: 493–504.
DevreeseKPeerlinckKHoylaertsMF. Diagnostic test combinations associated with thrombosis in lupus anticoagulant positive patients. Thromb Haemost2011; 105: 736–738.
10.
PengoVBiasioloAPegoraroC, et al.Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost2005; 93: 1147–1152.
11.
PengoVRuffattiALegnaniC, et al.Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost2010; 8: 237–242.
12.
MiyakisSLockshinMDAtsumiT, et al.International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
13.
PengoVDenasGZoppellaroG, et al.Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood2018; 132: 1365–1371.
14.
PengoVBanzatoABisonE, et al.Laboratory testing for antiphospholipid syndrome. Int J Lab Hematol2016; 38(Suppl 1): 27–31.
15.
DevreeseKMPierangeliSSde LaatB, et al.Subcommittee on lupus anticoagulant/phospholipid/dependent A: testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost2014; 12: 792–795.
16.
PontaraECattiniMGChengC, et al.Insight into the hypercoagulable state of high-risk thrombotic APS patients: contribution of abeta2GPI and aPS/PT antibodies. J Thromb Haemost2021; 19: 805–813.
17.
CointeSJudiconeCRobertS, et al.Standardization of microparticle enumeration across different flow cytometry platforms: results of a multicenter collaborative workshop. J Thromb Haemost2017; 15: 187–193.
18.
VikerforsAMobarrezFBremmeK, et al.Studies of microparticles in patients with the antiphospholipid syndrome (APS). Lupus2012; 21: 802–805.
19.
NiccolaiESquatritoDEmmiG, et al.A new cytofluorimetric approach to evaluate the circulating microparticles in subjects with antiphospholipid antibodies. Thromb Res2015; 136: 1252–1258.
20.
BurgerDSchockSThompsonCS, et al.Microparticles: biomarkers and beyond. Clin Sci (Lond)2013; 124: 423–441.
21.
LiuMLWilliamsKJ. Microvesicles: potential markers and mediators of endothelial dysfunction. Curr Opin Endocrinol Diabetes Obes2012; 19: 121–127.
22.
CombesVSimonACGrauGE, et al.In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest1999; 104: 93–102.
23.
BetapudiVLominadzeGHsiL, et al.Anti-beta2GPI antibodies stimulate endothelial cell microparticle release via a nonmuscle myosin II motor protein-dependent pathway. Blood2013; 122: 3808–3817.
24.
De GrootPGUrbanusRT. The significance of autoantibodies against beta2-glycoprotein I. Blood2012; 120: 266–274.
25.
BaroniGBanzatoABisonE, et al.The role of platelets in antiphospholipid syndrome. Platelets2017; 28: 762–766.
26.
PontaraEChengCCattiniMG, et al.An in vitro model to mimic the thrombotic occlusion of small vessels in catastrophic antiphospholipid syndrome (CAPS). Lupus2019; 28: 1663–1668.
27.
RidgerVCBoulangerCMAngelillo-ScherrerA, et al.Microvesicles in vascular homeostasis and diseases. Position paper of the European society of cardiology (ESC) working group on atherosclerosis and vascular biology. Thromb Haemost2017; 117: 1296–1316.
28.
ChaturvediSCockrellEEspinolaR, et al.Circulating microparticles in patients with antiphospholipid antibodies: characterization and associations. Thromb Res2015; 135: 102–108.
29.
JyWTiedeMBidotCJ, et al.Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies. Thromb Res2007; 121: 319–325.
30.
BreenKASanchezKKirkmanN, et al.Endothelial and platelet microparticles in patients with antiphospholipid antibodies. Thromb Res2015; 135: 368–374.
31.
HapponenKETranSMorgelinM, et al.The gas6-axl protein interaction mediates endothelial uptake of platelet microparticles. J Biol Chem2016; 291: 10586–10601.
32.
MobarrezFGunnarssonISvenungssonE. Altered beta2 -glycoprotein I expression on microparticles in the presence of antiphospholipid antibodies. J Thromb Haemost2017; 15: 1799–1806.
33.
CattiniMGBisonEPontaraE, et al.Tetra positive thrombotic antiphospholipid syndrome: major contribution of anti-phosphatidyl-serine/prothrombin antibodies to lupus anticoagulant activity. J Thromb Haemost2020; 18: 1124–1132.
34.
ChayouaWNicolsonPLRMeijersJCM, et al.Antiprothrombin antibodies induce platelet activation: a possible explanation for anti-FXa therapy failure in patients with antiphospholipid syndrome?J Thromb Haemost2021; 19: 1776–1782.
35.
FailleDEl-AssaadFMitchellAJ, et al.Endocytosis and intracellular processing of platelet microparticles by brain endothelial cells. J Cell Mol Med2012; 16: 1731–1738.
36.
ProulleVFurieRAMerrill-SkoloffG, et al.Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. Blood2014; 124: 611–622.
37.
Dignat-GeorgeFCamoin-JauLSabatierF, et al.Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost2004; 91: 667–673.
38.
VieraAJMooberryMKeyNS. Microparticles in cardiovascular disease pathophysiology and outcomes. J Am Soc Hypertens2012; 6: 243–252.
39.
BontadiARuffattiAFalcinelliE, et al.Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome. Thromb Haemost2013; 109: 901–908.
40.
RautouPEMackmanN. Del-etion of microvesicles from the circulation. Circulation2012; 125: 1601–1604.
